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The development of new therapeutic strategies for glioblastoma is very important to improve survival of patients and, finally, to remove tumor. Gene therapy using
shRNA anti-TERT has not been verified yet, but it could be a successful treatment and its research can help us to understand better the complex disease of cancer.
To determine the effect of direct administration of lentiviral vectors with shRNA anti-TERT into primary 
glioblastoma tumors using patient-derived tumor xenografts
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4. shRNA and telomerase for glioblastoma 3. Telomerase-based therapies for glioblastoma
Telomere shortening is the first step to tumoral
development, following by reactivation of telomerase
(Image 2) expression, which allows cellular
immortality [2]. 85% of primary human tumors, like
GBM, present telomerase activity [3]. New functions
of this enzyme are related to tumorigenesis too [4].
1. Glioblastoma: unresolved therapeutic challenge
Glioblastoma (GBM) is the most frequent and aggressive cerebral tumor, due to
its ability to invade the adjacent brain parenchyma (Image 1).
To design and to generate a shRNA to produce gene silencing of TERT and validate it in vitro, using gene 
therapy to deliver the therapeutic transgene to target cells
CONCLUSIONS
To study the ability of shRNA anti-TERT to decrease glioblastoma recurrence by means of the use of patient-
derived tumor xenografts treated after surgical resection of tumor
The development of new and effective
therapeutic strategies for glioblastoma
is the future goal.
Image 2. Telomerase is a large
ribonucleoprotein complex which adds
telomere repeats to chromosome ends.
TERT subunit: reverse transcriptase
activity; TERC subunit: RNA template [5].
THERAPY EXPLANATION DISADVANTAGES
Inmunotherapy[4]
Telomerase as antigen Immune privilege
of the brain
Telomeric 
disruption [4] 
TERC mutation: telomeric repair 
inhibition
Complex use in vivo / incomplet 
inhibition of telomerase functions
Oncolytic virus
[4]
TERT promoter drive expression of 
suicide genes
Non-reversible treatment
Telomerase 
inhibitor [4]
Imetelstat: RNA TERC inhibition, 
depletes glioma stem cells (GSC)
Systemic administration and 
temporal action
Table 1. Explanation of each telomerase-based therapies and its disadvantages.
New therapeutic strategy for GBM: telomerase gene silencing using shRNA
For these reasons, and for its specific
expression, telomerase is a good
therapeutic target against cancer.
Glioblastoma is an aggressive tumor with high recurrence and current treatments can not remove it at all. For these reasons, new therapeutic approaches are needed.
Telomerase is a good target to generate a new therapy for glioblastoma, because its expression is almost specific of tumoral cells, it has other cancer-related functions
and GSC can be affected targeting telomerase. Local administration in the brain avoids systemic toxicity and adverse effects in normal cells that express telomerase.
The complete eradication of glioblastoma using shRNA anti-TERT may not be achieved due to complexity and heterogeneity in tumors. Despite this, a high decrease of
tumoral cells and GSC is expected, and for that, a high survival in treated xenografts. Adverse effects caused by transgene or lentiviral vector are not expected. If there
is not a elevated inhibition of glioblastoma cells, it can be performed a study to probe combined efficiency of shRNA anti-TERT with chemotherapy and radiotherapy.
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Current treatment consists in a surgical resection,
followed by radiation and chemotherapy. The
median survival for GBM patients is 15 months,
because of the high tumor recurrence [1].
Image 1. Different types of gliomas. Most of them 
become into glioblastoma  [1].
Image 4. Experimental process for objective 2. In step 2, CED: conventional enhanced delivery.
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(short hairping RNA, a type of interference RNA), which destroy TERT mRNA,
and lentiviral vectors [6], for local administration of this therapeutic transgene
shRNA anti-TERT. These vectors do not cross the blood-brain barrier.
GENE THERAPY WITH SHRNA ANTI-TERT: NEW THERAPEUTIC APPROACH FOR 
GLIOBLASTOMA
Julia García Currás. Genetics Degree, Universidad Autónoma de Barcelona 
2.Telomeres, telomerase and cancer
The treatment is specific of tumoral cells because the biggest part of normal
cells does not express telomerase. It can be used to treat glioblastoma directly,
or to decrease its recurrence. It is necessary to probe new therapies, like this, in
order to solve the therapeutic challenge of glioblastoma.
